Zyvox (linezolid)
Company: Pfizer
Disease: Gram-positive bacterial infections
Global 2013-14 sales: $1.35 billion
U.S. patent expiration date: May 2015

Pfizer's ($PFE) Zyvox revenues in the U.S. grew last year, but that may not be the case come its 2015 patent expiration. Currently the world's best-selling branded agent used to treat serious Gram-positive pathogens, Zyvox recorded a 1% revenue uptick in 2013 primarily due to increased demand in both the U.S. and Europe.

One generics maker has already presented a challenge: Last February, Apotex notified Pfizer that it had filed an ANDA with the FDA for a copy, asserting the invalidity of Zyvox's basic patent. The following month, the pharma giant hit back, filing an action against Apotex in district court for patent infringement. In December the action was settled, Pfizer said in its annual report.

For more:
Pfizer to pay $3.3M to settle Zyvox probe
FDA warns against imaging med, flags Zyvox interaction

-- Carly Helfand (email | Twitter)


Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.